Furthermore, inhibition of Bax rescues the neuronal loss in APP-overexpressing, iPSC-derived neurons, suggesting that inhibiting Bax can be explored as a potential therapeutic approach for AD associated with increased APP expression. This evidence concerns the gene APP and Alzheimer disease.